Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0235108 (
tense
)
2,176
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Phosphorylation by protein kinase A and dephosphorylation by protein phosphatase 1 modulate the inhibitory activity of
phospholamban
(
PLN
), the endogenous regulator of the sarco(endo)plasmic reticulum calcium Ca(2+) ATPase (SERCA). This cyclic mechanism constitutes the driving force for calcium reuptake from the cytoplasm into the myocite lumen, regulating cardiac contractility.
PLN
undergoes a conformational transition between a relaxed (R) and
tense
(T) state, an equilibrium perturbed by the addition of SERCA. Here, we show that the single phosphoryl transfer at Ser16 induces a more pronounced conformational switch to the R state in phosphorylated
PLN
(pPLN). The binding affinity of
PLN
to SERCA is not affected (K(d) values for the transmembrane domains of pPLN and
PLN
are approximately 60 microM), supporting the hypothesis that phosphorylation at Ser16 does not dissociate
PLN
from SERCA. However, the binding surface and dynamics in domain Ib (residues 22-31) change substantially upon phosphorylation. Since
PLN
can be singly or doubly phosphorylated at Ser16 and Thr17, we propose that these sites remotely control the conformation of domain Ib. These findings constitute a paradigm for how post-translational modifications such as phosphorylation in the cytoplasmic portion of membrane proteins control intramembrane protein-protein interactions.
...
PMID:Effects of Ser16 phosphorylation on the allosteric transitions of phospholamban/Ca(2+)-ATPase complex. 1656 56
We have used chemical synthesis, functional reconstitution, and electron paramagnetic resonance (EPR) to probe the functional dynamics of
phospholamban
(
PLB
), which regulates the Ca-ATPase (SERCA) in cardiac sarcoplasmic reticulum. The transmembrane domain of
PLB
inhibits SERCA at low [Ca(2+)], but the cytoplasmic domain relieves this inhibition upon Ser16 phosphorylation. Monomeric
PLB
was synthesized with Ala11 replaced by the 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid (TOAC) spin label, which reports peptide backbone dynamics directly.
PLB
was reconstituted into membranes in the presence or absence of SERCA. TOAC-
PLB
showed normal inhibitory function, which was reversed by phosphorylation at Ser16 or by micromolar [Ca(2+)]. EPR showed that the
PLB
cytoplasmic domain exhibits two resolved conformations, a
tense
T state that is ordered and a relaxed R state that is dynamically disordered and extended.
PLB
phosphorylation shifts this equilibrium toward the R state and makes it more dynamic (hyperextended). Phosphorylation strongly perturbs the dynamics of SERCA-bound
PLB
without dissociating the complex, while micromolar [Ca(2+)] has no effect on
PLB
dynamics. A lipid anchor synthetically attached to the N terminus of
PLB
permits Ca-dependent SERCA inhibition but prevents the phosphorylation-induced disordering and reversal of inhibition. We conclude that the relief of SERCA inhibition by
PLB
phosphorylation is due to an order-to-disorder transition in the cytoplasmic domain of
PLB
, which allows this domain to extend above the membrane surface and induce a structural change in the cytoplasmic domain of SERCA. This mechanism is distinct from the one that relieves
PLB
-dependent SERCA inhibition upon the addition of micromolar [Ca(2+)].
...
PMID:Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA. 1657 47